Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

IASO206 en Pacientes con Mieloma Múltiple Recaído/Refractario

6 de noviembre de 2026 actualizado por: Institute of Hematology & Blood Diseases Hospital, China

Un estudio exploratorio de seguridad y eficacia de IASO206 en pacientes con mieloma múltiple recidivante/refractario

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Tianjin, Porcelana
        • Reclutamiento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • Contacto:
        • Investigador principal:
          • gang An

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 18 to 75 years old, male or female;

  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);

  • Presence of measurable lesions during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;

  • ECOG score ≤ 2;

  • Expected survival time ≥12 weeks;

  • Subjects must have adequate organ function:

  • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥50×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤1.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
    • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • Left ventricular ejection fraction (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective contraceptive methods with tools or drugs from the time the subject signs the informed consent form until one year after administration;

  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;

  • Multiple myeloma patients with plasma cell leukemia;

  • Patients with amyloidosis;

  • Patients who have received autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

  • Patients who have received previous BCMA-targeted therapy;

  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;

  • Patients who have received other anti-tumor treatments requires an appropriate washout period:

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of corticosteroids during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;

  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;

  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;

  • Patient who needs chronic use of immunosuppressive agents;

  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;

  • Patients with a history of solid organ transplantation;

  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;

  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;

  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;

  • Patients who have received inactivated vaccines within 4 weeks before enrollment;

  • Women who are pregnant or breastfeeding;

  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;

  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);

  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);

  • Other situations considered unsuitable by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: IASO206

IASO206 will be administered in one infusion.

The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The incidence and severity of adverse events(AEs)
Periodo de tiempo: up to 2 years after IASO206 infusion

Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus.

All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 2 years after IASO206 infusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall response rate (ORR)
Periodo de tiempo: up to 2 years after IASO206 infusion

The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

up to 2 years after IASO206 infusion
Time to response (TTR)
Periodo de tiempo: up to 2 years after IASO206 infusion

The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

up to 2 years after IASO206 infusion
MRD negativity rate
Periodo de tiempo: up to 2 years after IASO206 infusion

The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

up to 2 years after IASO206 infusion
Duration of response (DOR)
Periodo de tiempo: up to 2 years after IASO206 infusion

The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

up to 2 years after IASO206 infusion
Progression-free survival (PFS)
Periodo de tiempo: up to 2 years after IASO206 infusion

The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

up to 2 years after IASO206 infusion
Overall survival (OS)
Periodo de tiempo: up to 2 years after IASO206 infusion

The time from the date of IASO206 infusion to the date of death from any reason.

up to 2 years after IASO206 infusion
Pharmacodynamics(PD)
Periodo de tiempo: up to 2 years after IASO206 infusion

The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

up to 2 years after IASO206 infusion
Pharmacokinetic Analysis(PK)
Periodo de tiempo: up to 24 month after IASO206 infusion

Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Periodo de tiempo: up to 24 month after IASO206 infusion

Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Periodo de tiempo: up to 24 month after IASO206 infusion

Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

up to 24 month after IASO206 infusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de enero de 2026

Finalización primaria (Estimado)

15 de diciembre de 2026

Finalización del estudio (Estimado)

15 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

9 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

22 de diciembre de 2025

Publicado por primera vez (Actual)

7 de enero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IIT2025097

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .